Merck & Co., Inc. (ETR:6MK)
Germany · Delayed Price · Currency is EUR | Market Cap | 172.44B |
| Revenue (ttm) | 54.17B |
| Net Income (ttm) | 13.97B |
| Shares Out | n/a |
| EPS (ttm) | 5.52 |
| PE Ratio | 12.34 |
| Forward PE | 8.66 |
| Dividend | 2.91 (4.28%) |
| Ex-Dividend Date | Jun 16, 2025 |
| Volume | 2,289 |
| Average Volume | 2,437 |
| Open | 68.60 |
| Previous Close | 69.90 |
| Day's Range | 67.20 - 68.80 |
| 52-Week Range | 65.50 - 109.60 |
| Beta | 0.40 |
| RSI | 44.04 |
| Earnings Date | Jul 29, 2025 |
About CTI BioPharma
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas, including oncology, vaccines, hospital acute care, cardiovascular, virology, neuroscience, and diabetes under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janu... [Read more]
Financial Performance
In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.
Financial StatementsNews
Merck Stock Is Almost A Classical Benjamin Graham Investment
Merck is good value for money. It is a highly profitable company. It fulfills almost all of Benjamin Graham's stock-picking criteria.
Merck & Co., Inc. (MRK) Q2 2025 Earnings Call Transcript
Merck & Co., Inc. (NYSE:MRK) Q2 2025 Earnings Conference Call July 29, 2025 9:00 AM ET Company Participants Caroline A. Litchfield - Executive VP & CFO Dean Y.
'Halftime' Committee Stocks on the Move: UnitedHealth, Merck, Royal Caribbean and Spotify
The Investment Committee debate some of their stocks on the move lower.
Merck CEO Sees Minimal EU Tariffs Impact, Warns Of Gardasil Challenges
Merck & Co. Inc. (NYSE: MRK) shares fell over 6% in early trading Tuesday after the pharmaceutical giant reported a mixed second-quarter earnings picture, with adjusted earnings surpassing analyst co...
US market today: Stocks edge higher as Fed meet, China tariff talks weigh; JetBlue, SoFi jump while Merck, UnitedHealth drag
Wall Street saw modest gains, with the S&P 500 and Nasdaq reaching new highs, as investors awaited the Federal Reserve's rate decision and developments in US-China trade talks. JetBlue and SoFi Techno...
Merck will lay off employees and shed some real estate to cut $3 billion in costs
Merck’s stock is falling after a rare revenue miss, and the announcement of a $3 billion cost-cutting plan that will include layoffs.
Merck & Co., Inc. 2025 Q2 - Results - Earnings Call Presentation
Merck Stock Falls After Layoff Announcement, Gardasil Sales Drop
Merck stock fell early Tuesday after Q2 results. The Dow Jones drugmaker plans for job cuts as part of restructuring initiative.
Merck Posts Q2 EPS Beat Revenue Slips
Merck plans $3 billion cost cuts by end of 2027, narrows full-year outlook
CNBC's Joe Kernen reports on the company's quarterly earnings results.
Merck plans $3B cost cuts as Keytruda faces patent cliff
Merck Stock Falls After Earnings on Revenue Miss and Job Cuts
Merck to Lay Off Workers and Narrows Guidance as Earnings Fall
Merck to cut jobs and costs as demand for Gardasil in China remains weak
Drugmaker Merck & Co on Tuesday announced job and cost cuts it said will save $3 billion a year as it posted lower second-quarter results due to continuing weak demand for its Gardasil vaccine in Chin...
Merck Non-GAAP EPS of $2.13 beats by $0.10, revenue of $15.81B misses by $60M
Merck plans $3 billion cost cuts by end of 2027, narrows full-year outlook
The multi-year effort comes as Merck prepares to offset revenue losses from the upcoming patent expiration of its blockbuster cancer drug Keytruda.
Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2025 Financial Results
Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2025. "Earlier this month, we were plea...
Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2025 Financial Results
RAHWAY, N.J.--(BUSINESS WIRE)--Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2025 Financial Results.
Evercore ISI's Umer Raffat on finding value in the beaten-down health care sector
Umer Raffat, Evercore ISI senior analyst, joins 'The Exchange' to discuss if there's a turnaround coming for the health care sector.
Merck Q2 Earnings Preview: What to expect?
After Merck, Chinese Biotech Hengrui Pharma Collaborates With GSK In Worth $12 Billion Pact
Chinese biotech company Hengrui Pharma partnered with GSK plc (NYSE: GSK) on Monday to develop up to 12 medicines . These agreements will add significant value to Hengrui’s globalization strategy and...
Merck & Co's Earnings Outlook
Merck & Co (NYSE: MRK) is set to give its latest quarterly earnings report on Tuesday, 2025-07-29. Here's what investors need to know before the announcement. Analysts estimate that Merck & Co will r...
How To Earn $500 A Month From Merck Stock Ahead Of Q2 Earnings
Merck & Co., Inc. MRK will release earnings results for the second quarter before the opening bell on Tuesday, July 29.
Sell Merck Stock Ahead Of Its Upcoming Earnings?
Merck (NYSE:MRK) is set to reveal its earnings on Tuesday, July 29, 2025. Historically, MRK stock has exhibited a trend of negative one-day returns following earnings announcements.
EQS-AFR: Merck Financial Services GmbH: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]
EQS Preliminary announcement financial reports: Merck Financial Services GmbH / Preliminary announcement on the disclosure of financial statements Merck Financial Services GmbH: Preliminary announceme...